Harman Patil

APICA (synthetic cannabinoid drug)

Updated on
Share on FacebookTweet on TwitterShare on LinkedIn
CAS Number  1345973-50-3
ChemSpider  29341717
3D model (Jmol)  Interactive image
PubChem CID  71308155
Formula  C24H32N2O
Molar mass  364.522 g/mol
APICA (synthetic cannabinoid drug) httpsuploadwikimediaorgwikipediacommonsthu
Legal status  CA: Schedule II DE: Anlage II (Prohibited) Illegal in China and Japan

APICA (2NE1, SDB-001, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide) is an indole based drug that acts as a potent agonist for the cannabinoid receptors.

It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in March 2012 as an ingredient in synthetic cannabis smoking blends, along with its indazole derivative APINACA (sold as "AKB48").

Structurally it closely resembles cannabinoid compounds from patent WO 2003/035005 but with an indole core instead of indazole, and a simple pentyl chain on the indole 1-position.

Pharmacological testing determined APICA to have an IC50 of 175 nM at CB1, only slightly less potent than JWH-018 which had an IC50 of 169 nM, but over four times more tightly binding than APINACA, which had an IC50 of 824 nM. The first published synthesis and pharmacological evaluation of APICA revealed that it acts as a full agonist at CB1 (EC50 = 34 nM) and CB2 receptors (EC50 = 29 nM). Furthermore, APICA possesses cannabis-like effects in rats, and appears to be less potent than JWH-018 but more potent than THC.

Legal Status

As of October 2015 APICA is a controlled substance in China.

References

APICA (synthetic cannabinoid drug) Wikipedia


Similar Topics
Douglas Aziz
Louise Renicks
Mohammad Saeedi
Topics